ClinicalTrials.gg
Status unknownNCT05696639BayysmcvUpdated Jan 25, 2023

SMCV Assessment on Brain Swelling in Patients With SAH

An observational study in Aneurysm, Subarachnoid Hemorrhage and Brain Swelling, sponsored by Shenzhen Baoan District People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-25.

Sponsored by Shenzhen Baoan District People's Hospital · Observational

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
198
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Cerebral swelling is a major complication following aneurysmal subarachnoid hemorrhage.This study is a retrospective cohort aimed to predict the extent of brain swelling. Cerebral venous assessment can identify the risk of brain swelling and improve surgical outcomes.

Read the detailed description

Cerebral swelling is a major complication following aneurysmal subarachnoid hemorrhage (SAH).This study is a retrospective cohort aimed to predict the extent of brain swelling (BS). Cerebral venous assessment can identify the risk of cerebral swelling and improve surgical outcomes. This study is a retrospective cohort analysis. Cerebral venous angiography (CVA) will be adopted and the superficial middle cerebral vein (SMCVs) will be evaluated.

02

Conditions studied

  • Aneurysm
  • Subarachnoid Hemorrhage
  • Brain Swelling
03

In context

Aneurysm

381 studies on the registry are indexed under Aneurysm; 78 are open to participants now.

This study's enrollment of 198 is above the median of 157 across 132 observational studies indexed under Aneurysm.

Browse Aneurysm studies →

Lead sponsor

This is the only study on the registry with Shenzhen Baoan District People's Hospital as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with an anterior communicating aneurysmal subarachnoid hemorrhage between January 2017 and December 2022 who underwent aneurysm embolization surgery, excluding patients with posterior communicating aneurysm, poor general condition or combined with pregnancy , malignant tumors.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

patients with anterior communicating aneurysm

Exclusion criteria

Exclusion Criteria:

Hunt-Hess grade I- patients with posterior communicating aneurysm, poor general condition or combined with pregnancy , malignant tumors were excluded.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
198 participants (actual)
Patient registry
No

Groups and cohorts

  • Undeveloped venous group

    patients with undeveloped cerebral venous

    Procedure: Aneurysm embolization

  • Well Developed venous group

    patients with well-developed cerebral venous

    Procedure: Aneurysm embolization

Interventions

  • ProcedureAneurysm embolization

    All patients underwent Aneurysm embolization surgery, the cerebral venous will be observed intraoperatively.

06

What researchers measure

Primary outcomes

  1. brain swelling

    grading of brain swelling

    Time frame: 2 weeks

07

Study locations

1 site
  • Shenzhen Baoan People's Hospital
    Shenzhen, Guangdong 518000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Dec 2022, 68 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Jan 25, 2023
StartActual
Apr 1, 2017
Primary completionActual
Dec 1, 2022
CompletionEst.
Dec 30, 2023
Last update
Jan 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05696639
Lead sponsor
Shenzhen Baoan District People's Hospital
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Apr 1, 2017
Primary completion
Dec 1, 2022
Completion
Dec 30, 2023 (estimated)
Last update
Jan 25, 2023

Study contacts

JIangang Hu, Phd
study director · The People Hospital of Shenzhen Baoan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion